Gastroenterology (all articles)
Perspective | Clinicians debate the usefulness of NAFLD name change
11 Aug, 2023 | 15:39h | UTCClinicians debate the usefulness of NAFLD name change – MDedge
Original article: From NAFLD to MASLD | New consensus changes fatty liver disease terminology to avoid stigmatization
Cohort Study | Moderate to heavy drinking linked to increased risk of early-onset colorectal cancer
9 Aug, 2023 | 15:27h | UTCCommentary: Association of Alcohol Intake With Risk of Early-Onset Colorectal Cancer – The ASCO Post
Commentary on Twitter
🧐 Moderate/heavy alcohol intake linked to increased risk of early-onset #ColorectalCancer, particularly distal colon & rectal cancers ➡️ https://t.co/2akaNsHbLu #CRCSM pic.twitter.com/5DGrrmdX4i
— Journal of Clinical Oncology (@JCO_ASCO) July 18, 2023
M-A | Percutaneous catheter drainage superior to needle aspiration for liver abscess treatment success
9 Aug, 2023 | 15:12h | UTC
Proposed algorithm for appropriate fluid management in acute pancreatitis
8 Aug, 2023 | 13:33h | UTCFluid treatment in acute pancreatitis: a careful balancing act – British Journal of Surgery
Related:
Update on the management of acute pancreatitis – Current Opinion in Critical Care
Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis – New England Journal of Medicine
Acute Pancreatitis: Diagnosis and Treatment – Drugs
Evidence-Based Disposition of Acute Pancreatitis – emDocs
Pancreatitis – National Institute for Health and Care Excellence
Research: Endoscopic or Surgical Step-up Approach for Infected Necrotising Pancreatitis
Evidence-Based Approach to the Surgical Management of Acute Pancreatitis – The Surgery Journal
Clinical Trial Update | Long-term Givosiran treatment shows sustained acute hepatic porphyria symptom improvement
8 Aug, 2023 | 13:05h | UTCOriginal Study: Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria – New England Journal of Medicine
Review | Diagnosis and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome
4 Aug, 2023 | 11:50h | UTC
ACP Guidance | Asymptomatic CRC screening advised from age 50 with fecal occult blood test every 2 years or colonoscopy every 10 years
3 Aug, 2023 | 13:48h | UTCNews Release: ACP issues updated guidance for colorectal cancer screening of asymptomatic adults – American College of Physicians
Commentary: Start screening for colorectal cancer at age 50 years, ACP suggests – ACP Internist
Summary for Patients: Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults – Annals of Internal Medicine
Review | Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
1 Aug, 2023 | 14:19h | UTCRelated:
From NAFLD to MASLD | New consensus changes fatty liver disease terminology to avoid stigmatization
Nonalcoholic fatty liver disease from a primary care perspective – Diabetes, Obesity and Metabolism
Management of NAFLD in primary care settings – Liver International
Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports
RCT | Bictegravir regimen noninferior to dolutegravir regimen in HIV-1, HBV co-infection treatment
31 Jul, 2023 | 14:00h | UTC
AGA clinical practice update on evaluation and management of belching, abdominal bloating, and distention
27 Jul, 2023 | 13:04h | UTC
Review | Pediatric-onset inflammatory bowel disease: recent developments
27 Jul, 2023 | 12:57h | UTCInflammatory bowel disease: recent developments – Archives of Disease in Childhood
Podcast | Celiac disease pearls
27 Jul, 2023 | 12:53h | UTC#89: Celiac Disease – The Great Mimicker – The Cribsiders
Cohort Study | Proton pump inhibitor use linked to increased fatigue in kidney transplant recipients
26 Jul, 2023 | 13:21h | UTC
Commentary on Twitter
Proton Pump Inhibitor Use, Fatigue, and Health-Related Quality of Life in Kidney Transplant Recipients: Results From the TransplantLines Biobank and Cohort Study https://t.co/DkDTvs9zjo #OpenAccess#VisualAbstract @umcg pic.twitter.com/XooY16qFVT
— AJKD (@AJKDonline) July 25, 2023
Systematic Review | Dual therapy of Rifaximin and lactulose potentially reduces risk in hepatic encephalopathy
24 Jul, 2023 | 12:57h | UTC
RCT | Combined pre-operative olanzapine regimen lowers postoperative nausea in high-risk cancer patients
24 Jul, 2023 | 12:49h | UTC
Systematic Review | Medical treatment of eosinophilic esophagitis
21 Jul, 2023 | 13:27h | UTCMedical treatment of eosinophilic esophagitis – Cochrane Library
Summary: Medical treatments for eosinophilic esophagitis – Cochrane Library
Related:
M-A | Efficacy of elimination diets in eosinophilic esophagitis
RCT | Dupilumab in adults and adolescents with eosinophilic esophagitis
M-A | Hepatic, extra-hepatic outcomes and causes of mortality in NAFLD
20 Jul, 2023 | 10:59h | UTC
Systematic Review | Vedolizumab for induction and maintenance of remission in Crohn’s disease
20 Jul, 2023 | 10:51h | UTCVedolizumab for induction and maintenance of remission in Crohn’s disease – Cochrane Library
Large bowel obstruction | ED presentation, evaluation, and management
19 Jul, 2023 | 14:17h | UTCLarge bowel obstruction: ED presentation, evaluation, and management – emDocs
RCT | Midodrine show promise as an alternative to albumin for the prevention of circulatory disturbance in paracentesis between 3 and 5 L
18 Jul, 2023 | 13:47h | UTC
AHA Statement | Indications, evaluation, and outcomes for dual heart-kidney and heart-liver transplantation
14 Jul, 2023 | 12:51h | UTC
EASL Guidelines on the management of liver diseases in pregnancy
13 Jul, 2023 | 13:05h | UTC
AASLD Guidance | Use of TIPS, variceal embolization, and retrograde transvenous obliteration in variceal hemorrhage
11 Jul, 2023 | 13:59h | UTC
Guideline | Acute liver failure
10 Jul, 2023 | 13:59h | UTCAcute Liver Failure Guidelines – The American Journal of Gastroenterology
Related:
EASL Clinical Practice Guidelines on acute-on-chronic liver failure – Journal of Hepatology
Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU
Acute-on-chronic liver failure: far to go—a review – Critical Care
RCT | Mirikizumab outperforms placebo in inducing and maintaining remission in ulcerative colitis
10 Jul, 2023 | 13:25h | UTCMirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Mirikizumab Bests Placebo in Treating Patients With Ulcerative Colitis – HCP Live
Commentary on Twitter
In two placebo-controlled, phase 3 trials, mirikizumab, a p19-directed anti–interleukin-23 antibody, was superior with regard to clinical remission of ulcerative colitis at 12 weeks (induction) and 40 weeks (maintenance). https://t.co/H4reu33hF1
— NEJM (@NEJM) June 28, 2023